What question did this study set out to answer?

This research aims to investigate the role of the GM-CSF-IRF5 axis in TLR7-mediated macrophage activation syndrome (MAS).

GM-CSF-IRF5 Axis as a Therapeutic Target in TLR7-Mediated Macrophage Activation Syndrome 2309192

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates GM-CSF-IRF5 pathway in macrophage activation syndrome, suggesting novel therapeutic targets.

This research aims to investigate the role of the GM-CSF-IRF5 axis in TLR7-mediated macrophage activation syndrome (MAS).
Wild type, Irf5—/—, and GM-CSF—/— mice received topical R848 treatment to activate TLR7.
Flow cytometry quantified blood monocytes and inflammatory hemophagocytes (iHPCs).
Cytokine levels (GM-CSF, IL-12, IL-6, TNFα) were measured using LegendPlex assays.
Topical R848 treatment increased Ly6C^hi monocytes and iHPCs in WT mice, correlating with anemia and inflammation.
Irf5—/— and GM-CSF+/— mice exhibited reduced GM-CSF levels and protective effects against MAS symptoms.
Irf5 deficiency significantly decreased Ly6C^hi monocytes and iHPCs, preventing anemia and restoring hematopoietic balance.

Lu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark